MannKind Corporation Common Stock (MNKD)

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

591

Website

mannkindcorp.com/

Fundamentals

1-day range

$3.93$4.08

Market cap

$1.21B

P/E (trailing)

—

P/E (forward)

30.98

EPS (trailing)

$-0.14

Dividend yield

—

Beta

1.10

Avg. volume

5.00M

Dividend pay date

March 3, 2017

Forecasts

8 analyst ratings

MannKind Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• MNKD

  MannKind Corporation Common Stock

  $3.96

  ▼ 2.59%
  Market cap $1.21BP/E —
  $2.23$6.51
• LBRX

  LB Pharmaceuticals Inc Common Stock

  $47.8

  ▼ 0.20%
  Market cap $1.23BP/E —
  $13.36$50.16
• ARDX

  Ardelyx Inc. Common Stock

  $3.81

  ▼ 0.26%
  Market cap $1.23BP/E —
  $3.73$8.4
• ETON

  Eton Pharmaceuticals Inc. Common Stock

  $59.79

  ▼ 4.60%
  Market cap $1.24BP/E 150.92
  $14.27$66.37
• SDGR

  Schrodinger Inc. Common Stock

  $19.7

  ▼ 3.48%
  Market cap $1.14BP/E —
  $10.95$23.02
• CRVS

  Corvus Pharmaceuticals Inc. Common Stock

  $14.15

  ▼ 3.87%
  Market cap $1.12BP/E —
  $5.28$26.95
• SVRA

  Savara Inc. Common Stock

  $5.27

  ▼ 4.10%
  Market cap $1.09BP/E —
  $3.19$7.01

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants
  benzinga · 8/21/2026
• MannKind Files Prospectus For Resale By Selling Stockholders Of Up to 12,853,470 Shares, Including 2,412,632 Shares Underlying Pre-Funded Warrants
  Benzinga · 8/21/2026
• MannKind: New Approvals Majorly Increase MannKind's Prospects
  SeekingAlpha · 8/13/2026
• MannKind Corporation 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13
  Benzinga · 8/6/2026
• MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/5/2026
• MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue
  ChartMill · 8/5/2026
• MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate
  Benzinga · 8/5/2026
• MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload - Slideshow
  SeekingAlpha · 7/31/2026

• Steven B. Binder · August 7, 2026 · Sale

  39.1K @ $4.06
• Steven B. Binder · July 17, 2026 · Sale

  52.5K @ $4.06
• David Thomson · July 17, 2026 · Sale

  24.1K @ $4.05
• Dominic Marasco · July 15, 2026 · Tax Withholding

  3.6K @ $4.09
• Sanjay R. Singh · July 15, 2026 · Option Exercise

  70.5K
• Sanjay R. Singh · July 15, 2026 · Tax Withholding

  9.3K @ $4.09
• Sanjay R. Singh · July 15, 2026 · Tax Withholding

  10.1K @ $4.09
• Sanjay R. Singh · July 15, 2026 · Tax Withholding

  5.4K @ $4.09
• Sanjay R. Singh · July 15, 2026 · Tax Withholding

  22.0K @ $4.09
• Christopher B. Prentiss · July 15, 2026 · Tax Withholding

  10.7K @ $4.09
• Christopher B. Prentiss · July 15, 2026 · Tax Withholding

  11.6K @ $4.09
• Steven B. Binder · July 15, 2026 · Option Exercise

  93.8K
• Steven B. Binder · July 15, 2026 · Tax Withholding

  4.6K @ $4.09
• Steven B. Binder · July 15, 2026 · Tax Withholding

  4.1K @ $4.09
• Steven B. Binder · July 15, 2026 · Tax Withholding

  15.7K @ $4.09

Institutional Ownership

March 31, 2026

Total shares held

177.01M

Total value held

$432.04M

Institutional holders

243